Cell Lysis News and Research

RSS

MO BIO Laboratories introduces UltraClean-htp 96 Well Swab DNA Kit

MO BIO Laboratories, Inc., the leader in microbial, stool, plant, and soil nucleic acid purification, announces the launch of the UltraClean-htp 96 Well Swab DNA Kit. The kit is designed for rapid mechanical lysis of microbial cells from low biomass and low inhibitor containing swabs, paper or filter paper for direct application to PCR for metagenomic analysis.

2 Oct 2013

New reagent kits for intracellular staining from Beckman Coulter Life Sciences

PerFix-Expose1 and PerFix-nc1, innovative new reagent kits for intracellular staining from Beckman Coulter Life Sciences, minimize sample manipulation for a streamlined workflow that delivers high quality results. Developed for use on Beckman Coulter’s Gallios1 and Navios2 series flow cytometers and compatible with all Beckman Coulter Life Sciences’ fluorochromes, the kits enable a clear focus on the cytoplasmic and nuclear compartments of the cell.

8 Aug 2013

Combination of tPA with infusion of antiplatelet drug dissolves blood clots safely

The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati (UC) researchers has found.

31 Jul 2013

Clinical trial begins on ultrasound in combination with tPA to treat acute ischemic stroke

An international, Phase III clinical trial studying ultrasound in combination with a clot-busting medication to treat acute ischemic stroke has begun at The University of Texas Health Science Center at Houston (UTHealth).

12 Jul 2013

Modified measure quickly and effectively gauges intraventricular hemorrhage

Researchers have modified the Graeb score to produce a reliable, simple, quick, and clinically meaningful approximation of intraventricular hemorrhage volume.

11 Feb 2013

‘Ambu-lysis’ edges closer for stroke patients

A pilot trial of giving suitable stroke patients intravenous thrombolysis before their arrival in hospital has produced promising results.

17 Dec 2012

Akonni receives NSF's Phase 2 SBIR Grant to develop Lab-on-a-Film microarray

Akonni Biosystems, a life science tools / molecular diagnostics company that develops, manufactures, and plans to market molecular testing devices for diagnosing infectious diseases and human genetic disorders, announced today the receipt of a $498,780 Phase 2 SBIR Grant from the National Science Foundation (NSF).

6 Sep 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Fluidigm unveils details of new C1 Single-Cell AutoPrep System at ISSCR meeting

Fluidigm today unveiled the details of its new C1 Single-Cell AutoPrep System to attendees at the International Society for Stem Cell Research (ISSCR) meeting in Yokohama, Japan.

13 Jun 2012

Science journal’s NEWSFOCUS section describes recent advances in sequencing technology

Rapid DNA sequencing may soon become a routine part of each individual's medical record, providing enormous information previously sequestered in the human genome's 3 billion nucleotide bases. This week's NEWSFOCUS section of the journal Science describes recent advances in sequencing technology.

From Oxford Nanopore Technologies 23 May 2012

Birmingham hip resurfacings OK for men, but not for women

A study by G. Coulter, D. A. Young, R. E. Dalziel, and A. J. Shimmin, published this month in The Journal of Bone & Joint Surgery (British Volume) reports on the findings of an independent review of 230 consecutive Birmingham hip resurfacings (BHRs) in 213 patients (230 hips) at a mean follow-up of 10.4 years (9.6 to 11.7).

2 Mar 2012

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

BioInvent announces new BI-505 preclinical data on multiple myeloma

BioInvent International AB announced today that new preclinical data has been presented on its BI-505 programme that demonstrates anti-cancer activity in multiple myeloma and beneficial effect on bone density.

12 Dec 2011

Nanomedicine breakthrough by IBN and IBM named a ‘world changer’

A nanoparticle that can destroy drug-resistant bacteria developed by the Institute of Bioengineering and Nanotechnology (IBN), and the IBM Almaden Research Center, has recently been named one of 10 world changing ideas by Scientific American in its Technology Special Report ('World Changing Ideas – 10 New Technologies That Will Make a Difference', December 2011).

29 Nov 2011

Amorfix provides update on cancer therapeutic antibody programs

Amorfix Life Sciences Ltd., a product development company focused on diagnostics and therapeutics for misfolded protein diseases, provides an update on its cancer therapeutic antibody programs.

12 Aug 2011

Gene therapy to combat leukemia

In a medical breakthrough scientists have found that gene therapy could be used to cure leukemia. Researchers at the University of Pennsylvania engineered patients' own pathogen-fighting T-cells to target a molecule found on the surface of leukemia cells. These genetically modified T-cells were grown outside of the body and infused back into patients suffering from late-stage chronic lymphocytic leukemia (CLL), which affects the blood and bone marrow and is the most common form of leukemia.

11 Aug 2011

IntegenX's RapidHIT Human Identification Systems now include Promega's STR amplification reagents

IntegenX Inc. and Promega Corporation today announced that commercial deliveries of RapidHIT™ 200 Human Identification Systems will include Promega's nucleic acid purification and short tandem repeat (STR) amplification reagents.

4 Aug 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011